• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medtronic, FDA warn on potential cybersecurity risk with MiniMed insulin pump

September 20, 2022 By Sean Whooley

Medtronic MiniMed 670g insulin pump
Medtronic already decided to stop selling its MiniMed 670G insulin pump in February 2021 as it focuses on its 700 series devices. It still sells the MiniMed 630G. [Image from Medtronic]
Medtronic (NYSE:MDT) issued an urgent medical device correction notice to warn of potential issues with some MiniMed automated insulin delivery systems.

The notice — dated this month — covers the company’s MiniMed 600 series insulin pumps (MiniMed 630G and 670G). Affected devices also include the Guardian Link 3 transmitter, Contour Next Link 2.4 blood glucose monitor and the CareLink USB.

Medtronic recently identified a potential issue through internal testing with the devices. Under specific circumstances, unauthorized access could compromise communication between the pump system’s components. For such access to occur, a nearby person would need to gain access to the pump at the same time it is being paired with other system components. This can’t be done over the internet.

The company said it has no evidence to date that any such issue has occurred. Likewise, the FDA said it is not aware of any reports related to this cybersecurity vulnerability.

However, should unauthorized access happen, it could be used to deliver too much or too little insulin. The unauthorized person could deliver an unintended bolus or slow/stop insulin delivery.

In these cases, too much insulin may result in hypoglycemia (low blood sugar), potentially causing seizure, coma or death. Too little insulin could result in hyperglycemia (high blood sugar), which can lead to diabetic ketoacidosis (DKA).

The FDA said it is working with the company to identify, communicate, and prevent adverse events related to the cybersecurity vulnerability.

Medtronic provides actions for the user to take

Medtronic’s notice included required actions and recommended precautions for users. The company instructed users to turn off their “Remote Bolus” feature on the pump if turned on.

The notice recommends that users keep their pump and connected system components within their control at all times. Additionally, users should be attentive to notifications, alarms and alerts and cancel any boluses they or their care partner did not initiate.

Users should not confirm remote connection requests or other remote actions unless initiated by themselves or their care partner. They should not connect third-party devices to the MiniMed pump.

More trouble for Medtronic Diabetes?

Earlier this year, CEO Geoff Martha cited uncertainty over approval timing for Medtronic’s next-generation platforms. That includes the MiniMed 780G insulin pump and Guardian 4 CGM sensor.

Uncertainty comes as a result of a December 2021 FDA warning letter highlighting inadequacies in specific medical device quality system requirements at its Diabetes business’ Northridge, California, facility. Martha said on the company’s third-quarter earnings call that it achieved 90% of the FDA’s action items related to the warning.

Earlier this month, the law firm of Kessler Topaz Meltzer & Check announced a lawsuit in the U.S. District in Minnesota, claiming securities fraud over how Medtronic disclosed insulin pump problems.

Filed Under: Auto-injectors, Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pain Management, Recalls, Technology Tagged With: FDA, Medtronic

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS